Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for ONC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 1.488B
March 31, 2026 1.288B
December 31, 2025 1.131B
September 30, 2025 786.80M
June 30, 2025 571.97M
March 31, 2025 212.02M
December 31, 2024 -140.63M
September 30, 2024 -437.43M
June 30, 2024 -703.95M
March 31, 2024 -902.25M
December 31, 2023 -1.157B
September 30, 2023 -1.254B
June 30, 2023 -1.738B
March 31, 2023 -1.823B
December 31, 2022 -1.496B
September 30, 2022 -1.685B
June 30, 2022 -1.621B
March 31, 2022 -1.662B
December 31, 2021 -1.300B
September 30, 2021 -1.125B
Date Value
June 30, 2021 -973.75M
March 31, 2021 -816.42M
December 31, 2020 -1.283B
September 30, 2020 -1.218B
June 30, 2020 -1.137B
March 31, 2020 -920.24M
December 31, 2019 -750.27M
September 30, 2019 -676.98M
June 30, 2019 -544.16M
March 31, 2019 -615.19M
December 31, 2018 -547.72M
September 30, 2018 -260.07M
June 30, 2018 -121.29M
March 31, 2018 -56.04M
December 31, 2017 12.75M
September 30, 2017 -107.14M
June 30, 2017 -138.01M
March 31, 2017 -105.38M
December 31, 2016 -89.51M
September 30, 2016 -80.14M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Basilea Pharmaceutica AG 75.01M
Santhera Pharmaceuticals Holding AG -43.47M
AC Immune SA --
CRISPR Therapeutics AG -369.58M
Idorsia Ltd. -161.54M